TrialThe Lancet. Oncology2012

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Kent A Robertson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.